Comparing two drug combinations for untreated CLL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new combination of drugs (sonrotoclax plus zanubrutinib) against another standard combination (venetoclax plus acalabrutinib) for people with chronic lymphocytic leukemia (CLL) who have not had treatment before. The goal is to see which combination works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have CLL that hasn't been treated yet and now needs treatment.
- You should be able to perform daily activities with little to no help (ECOG score 0-2).
- You must have measurable disease that can be seen on a CT scan or MRI.
- Your bone marrow and major organs must be working well enough.
- You cannot have had any previous treatment for CLL.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of sonrotoclax plus obinutuzumab or rituximab versus the current standard venetoclax plus rituximab for people whose CLL or SLL has come back or not responded to previous treatment. The goal is to see which approach helps keep the cancer from growing longer.
This trial tests whether adding a new drug, sonrotoclax, to the standard treatment zanubrutinib works better for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who haven't had treatment before. It's for patients aged 65 and older who need therapy due to symptoms or blood cell issues.
This trial tests two different drug combinations (venetoclax with obinutuzumab or with acalabrutinib) to see how they affect the risk of tumor lysis syndrome in people with untreated CLL or SLL. It may help find the safest and most effective way to start treatment.
This trial tests a combination of three drugs (zanubrutinib, sonrotoclax, and obinutuzumab) for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have not had treatment before. The goal is to see if this combination works well and is safe.
This trial tests two different combinations of targeted drugs for people with CLL or SLL who have not had prior treatment for their disease. The goal is to see if these combinations are safe and effective.
This trial tests a combination of two targeted drugs (sonrotoclax and zanubrutinib) for people newly diagnosed with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who need treatment. It aims to see if using these drugs early can help achieve better deep responses.
Hear when a new Chronic Lymphocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.